Workflow
Nautilus platform
icon
Search documents
Nautilus Biotechnology Reports Second Quarter 2025 Financial Results
Globenewswire· 2025-07-31 12:00
Core Insights - Nautilus Biotechnology, Inc. reported significant advancements in its proteome analysis platform during Q2 2025, including the publication of a scientific manuscript showcasing novel data generated by its technology [2][3] - The company signed collaborations with major research institutes to utilize its platform for studying Tau proteoforms in relation to Alzheimer's disease, aiming to enhance understanding of disease-relevant biology [3] Financial Performance - Operating expenses for Q2 2025 were $17.1 million, an 18% decrease from $20.8 million in the same period last year, attributed to cost optimization and reduced salaries and professional services [4] - The net loss for Q2 2025 was $15.0 million, compared to a net loss of $18.0 million in the prior year [5] - As of June 30, 2025, the company had cash, cash equivalents, and investments totaling $179.5 million [5] Research and Development - The company continues to focus on both targeted and broadscale proteomic development efforts, demonstrating the effectiveness of its Iterative Mapping method for measuring proteoforms [2] - The collaborations with research institutes are expected to facilitate fundamental advances in understanding Alzheimer's disease progression [3]
Nautilus Biotechnology Reports First Quarter 2025 Financial Results
Globenewswire· 2025-04-29 12:00
Core Viewpoint - Nautilus Biotechnology, Inc. reported financial results for Q1 2025, highlighting progress in its Tau proteoform assay and a reduction in operating expenses, while also noting a net loss that improved compared to the previous year [1][2][4]. Financial Performance - Operating expenses for Q1 2025 were $18.8 million, a 13% decrease from $21.6 million in Q1 2024, attributed to cost optimization and reduced stock-based compensation [3]. - The net loss for Q1 2025 was $16.6 million, compared to a net loss of $18.7 million in the same period last year [4][12]. - Cash, cash equivalents, and investments totaled $192.8 million as of March 31, 2025 [4]. Business Development - The CEO emphasized the assay's reproducibility, accuracy, and compatibility with customer needs, indicating confidence in the platform's application in Alzheimer's and neurodegenerative disease research in 2025 [2]. - The company is focused on advancing its proteome analysis platform, aiming to democratize access to proteomics and enhance research capabilities in human health [6]. Cash Flow and Investments - Cash flows from operating activities showed a net cash used of $13.9 million for Q1 2025, an improvement from $16.3 million in Q1 2024 [13]. - The company generated $19.5 million from investing activities, primarily from securities maturities [14]. Balance Sheet Overview - Total assets as of March 31, 2025, were $227.7 million, down from $242.7 million at the end of 2024 [10][11]. - Total liabilities were $33.3 million, slightly decreased from $34.0 million at the end of the previous year [11]. - Stockholders' equity was $194.4 million, down from $208.7 million at the end of 2024, with an accumulated deficit of $289.6 million [11].